Skip to content

Released Nov 7, 2024, before the open

10-Q filed Nov 7, 2024, 38 days after period end · 0001785530-24-000034

Q3 2024 · 10-Q
Revenue—
Net Income-$16.67MN/M vs Q3 2023N/M vs Q2 2024
EPS Diluted-$0.38N/M vs Q3 2023N/M vs Q2 2024
Operating Income-$17,124,000N/M
Operating Cash Flowderived-$12,462,000N/M
Free Cash Flowderived-$12,465,000N/M

What the release said

The release

Same quarter

MetricQ3 2024Q3 2023Q3 2022Q3 2021
Net Income-$16.67M-$8.29M-$11.94M-$13.76M
EPS Diluted-$0.38-$0.23-$0.40-$0.51

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Werewolf Therapeutics, Inc. · CIK 1785530 · Engraved from SEC EDGAR